P. Tonin

发表

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Richard A. Moore, S. Fereday, D. Bowtell, 2010, The New England journal of medicine.

Identification of the breast cancer susceptibility gene BRCA2

D. Bentley, A. Ashworth, S. Seal, 1995, Nature.

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

J Chang-Claude, M. Stratton, J. Chang-Claude, 1998, American journal of human genetics.

An essential role for Ran GTPase in epithelial ovarian cancer cell survival

A. Mes-Masson, D. Provencher, P. Tonin, 2010, Molecular Cancer.

Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer.

C. Le Page, A. Mes-Masson, D. Provencher, 2007, Neoplasia.

Hereditary and familial ovarian cancer in southern ontario

P. Tonin, B. Rosen, H. Risch, 1994, Cancer.

Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women

M N Pollak, J C Zhang, L. Bégin, 1997, Cancer.

Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21.

J. Rommens, P. Tonin, S. Narod, 1995, Genomics.

BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.

B. Trock, K. Schulman, P. Tonin, 1996, JAMA.

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours

C. Greenwood, A. Mes-Masson, D. Provencher, 2011, PloS one.

Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.

M. King, M. Skolnick, D. Easton, 1996, American journal of human genetics.

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

O. Olopade, T. Rebbeck, B. Karlan, 2001, Pharmacogenetics.

SET complex in serous epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2006, International journal of cancer.

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations

Karim Oualkacha, Sahir Bhatnagar, Celia M. T. Greenwood, 2016, Front. Genet..

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population

A. Mes-Masson, D. Provencher, P. Tonin, 2015, Journal of Ovarian Research.

Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families

J. Rommens, M. Skolnick, P. Tonin, 1994, Nature Genetics.

Mutation Analysis of a Mauritian Hereditary Breast Cancer Family Reveals the BRCA2 6503delTT Mutation Previously Found to Recur in Different Ethnic Populations

P. Tonin, P. Ghadirian, Shadila Venkatasamy, 2001, Human Heredity.

Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study.

B. Godard, A. Mes-Masson, W. Foulkes, 1998, American journal of obstetrics and gynecology.

The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population

J. Ragoussis, C. Greenwood, A. Mes-Masson, 2022, Cancers.

LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS.

J. Ragoussis, C. Le Page, P. Tonin, 2020, Seminars in cancer biology.

Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.

O. Olopade, T. Rebbeck, W. Foulkes, 1998, Journal of the National Cancer Institute.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

C. Le Page, A. Mes-Masson, D. Huntsman, 2018, BMC Cancer.

Germline TP53 mutational spectrum in French Canadians with breast cancer

A. Mes-Masson, W. Foulkes, D. Provencher, 2015, BMC Medical Genetics.

The genetic basis of Muir-Torre syndrome includes the hMLH1 locus.

P. Tonin, S. Gallinger, S. Narod, 1996, American journal of human genetics.

Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling

Anne-Marie Mes-Masson, Véronique Ouellet, Thomas J Hudson, 2005, Oncogene.

Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.

A. Mes-Masson, D. Provencher, P. Tonin, 2012, International journal of oncology.

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

C. Le Page, A. Mes-Masson, J. Madore, 2007, Cancer.

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer

T. Hudson, C. Le Page, A. Mes-Masson, 2006, British Journal of Cancer.

BMP-2 signaling in ovarian cancer and its association with poor prognosis

C. Le Page, A. Mes-Masson, D. Provencher, 2009, Journal of ovarian research.

Identification of the breast cancer susceptibility gene BRCA2

Julian Peto, Peter Devilee, Rosalind Eeles, 1996, Nature.

Social, ethical and legal considerations raised by the discovery and patenting of the BRCA1 and BRCA2 genes

P. Tonin, Y. Joly, 2014 .

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history

A. Mes-Masson, P. Tonin, S. Narod, 1999, Clinical genetics.

A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3′ third of the gene

J. Chang-Claude, P. Tonin, B. Royer-Pokora, 1998, Human Genetics.

Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.

M. Skolnick, P. Tonin, J. Simard, 1996, Journal of medical genetics.

Hereditary nonpolyposis colon cancer: analysis of linkage to 2p15-16 places the COCA1 locus telomeric to D2S123 and reveals genetic heterogeneity in seven Canadian families.

P. Tonin, S. Narod, T. Young, 1994, American journal of human genetics.

Is hereditary site-specific ovarian cancer a distinct genetic condition?

W. Foulkes, P. Tonin, S. Narod, 1998, American journal of medical genetics.

BRCA1 mutations in Ashkenazi Jewish women.

P. Tonin, J. Simard, G. Lenoir, 1995, American journal of human genetics.

The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene

M. Stratton, N. Rahman, P. Tonin, 1997, Oncogene.

Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2002, Molecular carcinogenesis.

Brca2 hereditary breast cancer pathophenotype

P. Tonin, D. Page, G. Lenoir, 1997, Breast Cancer Research and Treatment.

Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations

C. Greenwood, A. Mes-Masson, W. Foulkes, 2004, International journal of cancer.

Mutation analysis oftheBRCA1genein23 families withcases ofcancer ofthebreast, ovary, andmultiple other sites

P. Tonin, J. Simard, F. Durocher, 1996 .

Mutations in a 10‐bp polyadenine repeat of transforming growth factor β‐receptor type II gene is an infrequent event in human epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2000, Clinical genetics.

Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A

A. Mes-Masson, D. Provencher, P. Tonin, 2004, Cancer Chemotherapy and Pharmacology.

Hereditary and familial ovarian cancer in southern ontario

P. Tonin, B. Rosen, H. Risch, 1994, Cancer.

OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer.

A. Mes-Masson, D. Provencher, P. Tonin, 2005, International journal of oncology.

Mutations in BRCA 1 and BRCA 2 in Breast Cancer Families : Are There More Breast Cancer-Susceptibility Genes ?

P. Tonin, Y. Shugart, S. Mazoyer, 2006 .

[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].

P. Tonin, 2006, Bulletin du cancer.

Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.

P. Chappuis, W. Foulkes, P. Tonin, 2001, Journal of the National Cancer Institute.

Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites

A. Mes-Masson, D. Provencher, P. Tonin, 1999, Molecular carcinogenesis.

Smoking and the risk of breast cancer among carriers of BRCA mutations

D. Horsman, W. Foulkes, B. Weber, 2004, International journal of cancer.

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers

A. Mes-Masson, D. Provencher, P. Tonin, 2000, Oncogene.

The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer.

H. Huynh, P. Tonin, G. Lenoir, 1993, Genomics.

Phenotypic and molecular characterization of inducible human neuroblastoma cell lines.

P. Tonin, H. Yeger, C. Kaplinsky, 1988, Differentiation; research in biological diversity.

Haplotype Analysis of BRCA2 8765delAG Mutation Carriers in French Canadian and Yemenite Jewish Hereditary Breast Cancer Families

A. Mes-Masson, W. Foulkes, D. Provencher, 2001, Human Heredity.

Amplification of N-myc and ornithine decarboxylase genes in human neuroblastoma and hydroxyurea-resistant hamster cell lines.

R. Stallings, P. Tonin, H. Yeger, 1989, Oncogene.

Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?

P. Tonin, Y. Shugart, G. Lenoir, 1997, American journal of human genetics.

Genetic and physical characterization of trimethoprim resistance plasmids from Shigella sonnei and Shigella flexneri.

P. Tonin, R. B. Grant, 1987, Canadian journal of microbiology.

Trisomy of chromosome 10 in two cases of ovarian carcinoma.

A. Mes-Masson, D. Provencher, P. Tonin, 2000, Cancer genetics and cytogenetics.

Histology of BRCA1-associated ovarian tumours

P. Tonin, G. Lenoir, H. Lynch, 1994, The Lancet.

Gene for M1 subunit of ribonucleotide reductase is amplified in hydroxyurea-resistant hamster cells

P. Tonin, J. Cocking, W. H. Lewis, 1987, Somatic cell and molecular genetics.

The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21.

P. Tonin, J. Simard, G. Lenoir, 1994, Human molecular genetics.

The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.

Anthony Magliocco, David Laperrière, Sylvie Mader, 2015, Cancer research.

Characterization of three new serous epithelial ovarian cancer cell lines

A. Mes-Masson, J. Madore, D. Provencher, 2008, BMC Cancer.

Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.

P. Tonin, W. Cavenee, H. Shimada, 1991, Cancer research.

Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations.

P. Tonin, M. Basik, J. Hébert, 2010, Cancer research.

Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance.

C. Greenwood, A. Mes-Masson, P. Tonin, 2013, Cancer genetics.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent

A. Mes-Masson, D. Provencher, P. Tonin, 2008, BMC Cancer.

Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage

G M Lenoir, P. Tonin, D. Page, 1996, Cancer.

Analysis of PALB2/FANCN-associated breast cancer families

Petra M. Nederlof, Jorge S. Reis-Filho, David M. Livingston, 2007, Proceedings of the National Academy of Sciences.

Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.

S. Bens, R. Siebert, A. Mes-Masson, 2017, Cancer research.

A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.

Paolo Radice, Fergus J Couch, Christian Singer, 2013, Cancer research.

RAD51C germline mutations in breast and ovarian cancer patients

Marc Tischkowitz, W. Foulkes, P. Tonin, 2010, Breast Cancer Research.

Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families

Y. Tabach, A. Mes-Masson, W. Foulkes, 2021, NPJ breast cancer.

High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families

J. Chang-Claude, B. Ponder, C. Larsson, 1995 .

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

A. Mes-Masson, W. Foulkes, D. Provencher, 1998, American journal of human genetics.

Mutation analysis of the BRCA2 gene in 49 site–specific breast cancer families

C. Larsson, J. Lancaster, P. Tonin, 1996, Nature Genetics.

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2021, Genome medicine.

The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene

J. Ragoussis, C. Greenwood, A. Mes-Masson, 2020, medRxiv.

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families

D. B. Berman, F. Couch, T. Rebbeck, 1996, Nature Medicine.

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

P. Chappuis, W. Foulkes, P. Tonin, 2002, Journal of medical genetics.

Whole‐exome sequencing of non‐BRCA1/BRCA2 mutation carrier cases at high‐risk for hereditary breast/ovarian cancer

J. Ragoussis, F. Couch, P. Tonin, 2020, Human mutation.

Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers

P. Tonin, W. M. Alenezi, C. T. Fierheller, 2020, Genes.

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines

J. Ragoussis, C. Greenwood, A. Mes-Masson, 2021, Cancers.

Characterization of the 3p12.3‐pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer

A. Mes-Masson, D. Provencher, P. Tonin, 2009, Molecular carcinogenesis.

RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2014, PloS one.

Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region

T. Hudson, A. Mes-Masson, D. Provencher, 2004, Molecular carcinogenesis.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

C. Le Page, A. Mes-Masson, D. Huntsman, 2018, BMC Cancer.

FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.

A. Mes-Masson, D. Provencher, P. Tonin, 2013, International journal of oncology.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

A. Mes-Masson, D. Huntsman, M. Köbel, 2010, The Journal of pathology.

Protease inhibitor SERPINA1 expression in epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2010, Clinical & Experimental Metastasis.

The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families

P. Tonin, W. M. Alenezi, C. T. Fierheller, 2021, Cancers.

Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer

W. Foulkes, D. Provencher, P. Tonin, 2021, Scientific Reports.

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women

W. Foulkes, P. Tonin, Longlong Chen, 2008, BMC Cancer.

Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon.

W. Foulkes, P. Tonin, S. Narod, 1996, Journal of medical genetics.

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome

C. Greenwood, A. Mes-Masson, J. Madore, 2012, PloS one.

L. Donehower, A. Langerød, L. Strong, 2017, Cancer research.

Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12–q21

Nazneen Rahman, Michael R. Stratton, Jerry Pelletier, 1996, Nature Genetics.

Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families

W. Foulkes, P. Tonin, K. Claes, 2012, British Journal of Cancer.

Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2023, Genes.

Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants

J. Ragoussis, A. Mes-Masson, W. Foulkes, 2022, Genes.

Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer

J. Ragoussis, A. Dimas, A. Mes-Masson, 2019, Frontiers in Genetics.

Genes implicated in hereditary breast cancer syndromes.

P. Tonin, 2000, Seminars in surgical oncology.

A descriptive study of BRCA1 testing and reactions to disclosure of test results

P. Tonin, S. Narod, H. Lynch, 1997, Cancer.

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer

P. Tonin, O. Kallioniemi, S. Mousses, 2012, Oncogene.

An absence of founder BRCA2 mutations in individuals with squamous cell carcinoma of the head and neck

W. Foulkes, P. Tonin, N. Hamel, 1999, International journal of cancer.

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity

A. Mes-Masson, D. Provencher, P. Tonin, 2012, Oncogenesis.

Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes

A. Mes-Masson, D. Provencher, P. Tonin, 2007, International Journal of Gynecologic Cancer.

Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.

T. Hudson, A. Mes-Masson, D. Provencher, 2007, International journal of oncology.

Chromosomal assignment of amplified genes in hydroxyurea-resistant hamster cells.

R. Stallings, P. Tonin, J. Bertino, 1987, Cytogenetics and cell genetics.

The gene for ornithine decarboxylase is co-amplified in hydroxyurea-resistant hamster cells.

P. Tonin, W. H. Lewis, P. R. Srinivasan, 1987, The Journal of biological chemistry.

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

A. Mes-Masson, J. Madore, D. Provencher, 2008, BMC Cancer.

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

Anne-Marie Mes-Masson, Liliane Meunier, A. Mes-Masson, 2012, BMC Cancer.

C. Greenwood, P. Tonin, A. Ferenczy, 2019, Molecular Cancer Research.

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease

A. Mes-Masson, D. Provencher, P. Tonin, 2015, Genes & cancer.

Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)

Anne-Marie Mes-Masson, Abdelali Filali-Mouhim, A. Mes-Masson, 2007, Molecular carcinogenesis.

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

A. Mes-Masson, D. Provencher, P. Tonin, 2015, BMC Cancer.

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families

A. Mes-Masson, W. Foulkes, D. Provencher, 2008, Breast Cancer Research and Treatment.

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.

A. Mes-Masson, D. Provencher, P. Tonin, 2015, Oncology letters.

BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers

P. Tonin, 2002 .

Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

A. Mes-Masson, D. Provencher, P. Tonin, 2012, Cancer Prevention Research.

A large multisite cancer family is linked to BRCA2.

P. Tonin, G. Lenoir, S. Narod, 1995, Journal of medical genetics.

Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.

L. Bégin, W. Foulkes, P. Tonin, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Linkage analysis of 26 Canadian breast and breast-ovarian cancer families

N. Boyd, P. Tonin, J. Simard, 1995, Human Genetics.

A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.

P. Tonin, G. Lenoir, S. Narod, 1996, American Journal of Human Genetics.

Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA.

P. Tonin, J. Simard, G. Rouleau, 1993, Human molecular genetics.

Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p

A. Mes-Masson, D. Provencher, P. Tonin, 2007, Oncogene.

The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors.

P. A. Futreal, C. Larsson, P. Tonin, 1996, Genomics.

Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1‐q25.2

K. Dewar, A. Mes-Masson, D. Provencher, 2005, Molecular carcinogenesis.

Confirmation of FWT1 as a Wilms’ tumour susceptibility gene and phenotypic characteristics of Wilms’ tumour attributable to FWT1

Michael R. Stratton, Dick Variend, Richard Grundy, 1998, Human Genetics.

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.

C. Le Page, A. Mes-Masson, D. Provencher, 2019, Gynecologic oncology.

Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

T. Hudson, A. Mes-Masson, D. Provencher, 2002, Genome research.

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

A. Mes-Masson, D. Provencher, P. Tonin, 2016, Oncotarget.

Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics

D. Huntsman, Colleen A Crane, B. Vanderhyden, 2013, Orphanet Journal of Rare Diseases.

VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2013, Molecular oncology.

Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer

C. Le Page, A. Mes-Masson, D. Provencher, 2006, International journal of cancer.

The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent

A. Mes-Masson, W. Foulkes, D. Provencher, 2011, Breast Cancer Research and Treatment.

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2010, Familial Cancer.

Characterization of four novel epithelial ovarian cancer cell lines

A. Mes-Masson, D. Provencher, P. Tonin, 2000, In Vitro Cellular & Developmental Biology - Animal.

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.

C. Greenwood, P. Tonin, A. Yasmeen, 2018, Gynecologic oncology.

Molecular Genetic Analysis of a Cell Adhesion Molecule With Homology to L1CAM, Contactin 6, and Contactin 4 Candidate Chromosome 3p26pter Tumor Suppressor Genes in Ovarian Cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2009, International Journal of Gynecologic Cancer.

Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2023, Frontiers in Oncology.

A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families

A. Mes-Masson, D. Provencher, P. Tonin, 2007, Familial Cancer.

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model

Anne-Marie Mes-Masson, Thomas J Hudson, T. Hudson, 2001, Oncogene.

Germ-Line BRCA 1 Mutation Is an Adverse Prognostic Factor in Ashkenazi Jewish Women with Breast Cancer 1

L. Bégin, W. Foulkes, P. Tonin, 2005 .

Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer

P. Tonin, A. Robidoux, N. Hamel, 2001, Clinical genetics.

Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes

A. Mes-Masson, D. Provencher, P. Tonin, 2008, Molecular carcinogenesis.

Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.

C. Le Page, A. Mes-Masson, D. Provencher, 2010, Translational oncology.

The gene for a novel protein, a member of the protein disulphide isomerase/form I phosphoinositide-specific phospholipase C family, is amplified in hydroxyurea-resistant cells.

P. Tonin, W. H. Lewis, P. R. Srinivasan, 1992, The Biochemical journal.

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families

Anne-Marie Mes-Masson, A. Mes-Masson, W. Foulkes, 2006, BMC Medical Genetics.

The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles

Anne-Marie Mes-Masson, A. Mes-Masson, D. Provencher, 2009, Journal of Translational Medicine.

Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2009, Molecular carcinogenesis.

Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines

T. Hudson, A. Mes-Masson, D. Provencher, 2003, Oncogene.

Mapping of chromosome 3p deletions in human epithelial ovarian tumors

A. Mes-Masson, D. Provencher, P. Tonin, 1998, Oncogene.

High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium.

B. Ponder, P. Tonin, D. Kelsell, 1995, Genes, chromosomes & cancer.

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines

A. Mes-Masson, D. Provencher, P. Tonin, 2008, BMC Medical Genomics.

Is there a correlation between the structure of hair and breast cancer or BRCA1/2 mutations?

W. Foulkes, P. Tonin, P. Ghadirian, 2002, Physics in medicine and biology.

Biomarkers in Epithelial Ovarian Cancer—or Should We Go with the Flow?

O. Guenat, A. Mes-Masson, D. Provencher, 2012 .

Authors' Reply

A. Mes-Masson, D. Huntsman, M. Köbel, 2010 .

Genetic and molecular analyses of candidate germline BRIP1/FANCJ variants implicated in breast and ovarian cancer

J. Ragoussis, A. Mes-Masson, D. Provencher, 2023, medRxiv.

BRCA1 mutations and survival in women with ovarian cancer.

W. Foulkes, P. Tonin, J. Brunet, 1997, The New England journal of medicine.

From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer

T. Hudson, C. Le Page, A. Mes-Masson, 2006, International journal of cancer.

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Steven E. Bayer, M. Skolnick, C. Lewis, 1994, Science.

cDNA sequence of the small subunit of the hamster ribonucleotide reductase.

P. Tonin, P. R. Srinivasan, M. Chaudhuri, 1992, Biochimica et biophysica acta.

Founder BRCA1 and BRCA2 mutations in early‐onset French Canadian breast cancer cases unselected for family history

W. Foulkes, P. Tonin, P. Ghadirian, 2001, International journal of cancer.

Calcified tissue of fetal origin in utero.

P. Tonin, J. Arseneau, T. Tulandi, 2008, Fertility and sterility.

BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer

C. Le Page, A. Mes-Masson, D. Provencher, 2008, Cancer Epidemiology Biomarkers & Prevention.

An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.

A. Whittemore, J. Chang-Claude, B. Ponder, 1995, American journal of human genetics.

Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour

S. Seal, M. Stratton, N. Rahman, 2005, Journal of Medical Genetics.

Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent

A. Mes-Masson, W. Foulkes, D. Provencher, 2013, BMC Medical Genetics.

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent

A. Mes-Masson, W. Foulkes, D. Provencher, 2006, Clinical genetics.

The quest for a tumor suppressor gene phenotype.

P. Tonin, N. Presneau, E. N. Manderson, 2003, Current molecular medicine.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Richard A. Moore, Allen D. Delaney, S. Fereday, 2010, The New England journal of medicine.

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Steven E. Bayer, M. Skolnick, L. Cannon-Albright, 1994, Science.

Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance.

C. Greenwood, A. Mes-Masson, P. Tonin, 2013, Cancer genetics.